Go-to-market (GTM) strategy for medical device startups

Quick answer

A go-to-market strategy for a medical device startup is built around evidence and the hospital's buying committee, not volume. Lead with clinical and economic proof, target the specific hospitals and clinicians your device genuinely fits, map the full value-analysis committee per account, and plan for biomed sign-off, procurement and GPO contracts from the start. Because cycles run 12 to 24 months across 8 to 15 stakeholders, the strategy has to include the CRM and follow-up that keep long deals alive until a purchase order lands. Evidence-led targeting plus the infrastructure to sustain the cycle is the whole game.

What makes device GTM different

A go-to-market strategy that works for software fails for devices, because the buyer and the cycle are fundamentally different. Medical devices sell into hospitals and health systems that buy slowly, through value-analysis committees, and demand clinical evidence before anyone signs. As the medical devices page puts it, a device can be clearly better and still take a year or more to land.

So device GTM is not a demand-generation sprint. It is the disciplined work of reaching the right clinical and economic buyers with evidence, navigating procurement and group purchasing contracts, and keeping a long, multi-stakeholder deal alive from first conversation to purchase order. The underlying revenue infrastructure is the same discipline covered in the RevOps for startups guide; this is how it is shaped for a device motion.

Who are you really selling to?

Not a buyer. A committee. A device decision runs through 8 to 15 stakeholders, and the GTM has to account for all of them. Drawing on the roles the medical devices page sets out:

Gartner has found the typical B2B buying group involves six to ten decision makers; devices sit at the top of that range and beyond. A GTM that targets a single "buyer" misreads the entire motion. Map the committee per account and plan to reach each role at the right point in the cycle.

How do you lead with evidence?

Value-analysis committees buy on proof, not promises, so evidence is the center of gravity for the whole strategy, not a late-stage attachment.

That means two things. First, build the evidence story before you scale outreach: the clinical and economic case a committee will actually accept, in the form they expect. Second, make evidence the opening move in targeting and messaging, aimed at the clinician who will champion it. The outbound and cold outreach for medical devices article covers how that lands in practice.

Be accurate about the regulatory reality. What you can claim about a device's clinical benefit is bounded by your clearances and the evidence you actually have. A GTM that overstates indications or outcomes does not just risk compliance problems; it destroys the credibility the whole committee decision rests on. Lead with evidence, and only with evidence you can stand behind.

How do you account for procurement and GPOs?

Even after a committee approves a device on clinical and economic merit, the deal still has to clear procurement, and often a group purchasing organization contract. GPOs negotiate pricing and terms on behalf of their member hospitals, and a device that is not on the right contract vehicle can stall at the final step.

Build this into the GTM from the start rather than discovering it at the end:

• Know which GPOs your target hospitals buy through, and what that means for pricing and access.
• Reach biomed and procurement early enough that safety sign-off and contracting are not last-minute surprises.
• Track contract and renewal timing per account, because a renewal window can be the moment a long deal finally moves.

Procurement is a gate to navigate, not an obstacle to bypass, and a GTM that respects it closes deals that an evidence-only strategy leaves stranded.

What infrastructure does the strategy need?

A device GTM is only as good as the system that sustains it, because the cycle is too long to hold in anyone's head. The infrastructure has three parts:

1. Evidence-led targeting. A defined list of the hospitals and clinicians the device genuinely fits, built on real clinical and economic fit signals, not a broad market.
2. A CRM built for long cycles. Accounts modeled as hospitals, the committee as contacts with roles, and fields for evidence status, biomed sign-off and GPO contracts. See CRM setup for medical device companies and the pipeline build.
3. Sustained, multichannel follow-up. Sequences that keep clinical champions and committees engaged across quarters, because the first conversation and the purchase order can be a year apart.

Without that infrastructure, a device GTM is a founder's memory and a spreadsheet, and both fail over a 12 to 24 month cycle.

How do you measure progress before revenue?

You cannot wait a year to know whether the GTM is working. Measure leading indicators that predict eventual deals:

• Target accounts with an engaged clinical champion.
• Evidence accepted by champions and value-analysis committees.
• Accounts that have cleared biomed or reached a committee agenda.
• Pipeline created and advancing through the gates, read over quarters.

These tell you the motion is generating real, committee-backed opportunities long before any purchase order, and they are what let you correct targeting or evidence early instead of a year too late.

Where Enablemnt fits

A device GTM is evidence-led targeting, committee mapping, procurement awareness and the CRM and follow-up to sustain a year-long cycle, all working together. It is weeks of setup, and building it while running the first deals is more than a founding team usually has capacity for.

Enablemnt is your embedded RevOps and outbound team, and we build this GTM foundation in a fixed 14-day sprint: evidence-led targeting, the committee mapped per account, a CRM made for long regulated cycles, and live outbound on top. It is the same two-week build described in build GTM infrastructure in 14 days, shaped for a device motion. You own all of it at the end, documented.

If you want a device go-to-market built right the first time rather than assembled over a year, tell us about your company and we will map your GTM blueprint on a short call.

Filed under By industry. Written by Enablemnt AI.